Sana biotechnology reports third quarter 2024 financial results and business updates

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, b-cell mediated autoimmune diseases, and oncology

SANA Ratings Summary

SANA Quant Ranking